Antiemetics: American Society of Clinical Oncology clinical practice guideline update

Journal of Clinical Oncology

Volumn 35, Issue 28, 2017, Pages 3240-3261

  Hesketh, Paul J ^a   Kris, Mark G ^c   Basch, Ethan ^d   Bohlke, Kari ^f   Barbour, Sally Y ^e   Clark Snow, Rebecca Anne ⁱ   Danso, Michael A ^g,h   Dennis, Kristopher ^m   Dupuis, L Lee ⁿ   Dusetzina, Stacie B ^d   Eng, Cathy ^j   Feyer, Petra C ^o   Jordan, Karin ^p   Noonan, Kimberly ^b   Sparacio, Dee ^k   Somerfield, Mark R ^f   Lyman, Gary H ^l  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^g Virginia Oncology Associates   (United States)

^h Virginia Oncology Associates   (United States)

ⁱ UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k Patient Representative   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m UNIVERSITY OF OTTAWA   (Canada)

ⁿ HOSPITAL FOR SICK CHILDREN   (Canada)

^o VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^p UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIEMETIC AGENT; APREPITANT; AZACITIDINE; BENDAMUSTINE; CANNABINOID; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; DRONABINOL; EPIRUBICIN; GRANISETRON; LORAZEPAM; NABILONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 ANTAGONIST; SEROTONIN ANTAGONIST; STREPTOZOCIN; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL SOCIETY; ONCOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INDUCED EMESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; NAUSEA; NEOPLASMS; PROCEDURES; STANDARDS; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NAUSEA; NEOPLASMS; VOMITING;

EID: 85030166801     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.4789     Document Type: Review

References (123)

1. Navari RM, Aapro M: Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356-1367, 2016
2. Aapro M, Molassiotis A, Dicato M, et al: The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol 23:1986-1992, 2012
3. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol 17: 2971-2994, 1999
4. Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24:2932-2947, 2006
5. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011
6. [Erratum: Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:2117, 2014]
7. Hesketh PJ, Bohlke K, Lyman GH, et al: Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34:381-386, 2016
8. Shojania KG, Sampson M, Ansari MT, et al: How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 147:224-233, 2007
9. Shiffman RN, Michel G, Rosenfeld RM, et al: Building better guidelines with BRIDGE-Wiz: Development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc 19:94-101, 2012
10. Roila F, Hesketh PJ, Herrstedt J: Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28, 2006
11. Jordan K, Chan A, Gralla RJ, et al: 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25:271-275, 2017
12. Albany C, Brames MJ, Fausel C, et al: Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: A Hoosier Oncology Group study. J Clin Oncol 30:3998-4003, 2012
13. Arslan M, Ozdemir L: Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clin J Oncol Nurs 19: E92-E97, 2015
14. Bakhshi S, Batra A, Biswas B, et al: Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: A randomized, double-blind, placebo-controlled trial. Support Care Cancer 23:3229-3237, 2015
15. Boccia RV, Gordan LN, Clark G, et al: Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: A randomized, double-blind, phase III study. Support Care Cancer 19:1609-1617, 2011
16. Enblom A, Johnsson A, Hammar M, et al: Acupuncture compared with placebo acupuncture in radiotherapy-induced nausea—A randomized controlled study. Ann Oncol 23:1353-1361, 2012
17. Genç A, Can G, Aydiner A: The efficiency of the acupressure in prevention of the chemotherapy-induced nausea and vomiting. Support Care Cancer 21:253-261, 2013
18. Hesketh PJ, Schnadig ID, Schwartzberg LS, et al: Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 122:2418-2425, 2016
19. Kang HJ, Loftus S, Taylor A, et al: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial. Lancet Oncol 16:385-394, 2015
20. Karthaus M, Tibor C, Lorusso V, et al: Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer 23:2917-2923, 2015
21. Komatsu Y, Okita K, Yuki S, et al: Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci 106:891-895, 2015
22. Kovács G, Wachtel AE, Basharova EV, et al: Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: A randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol 17:332-344, 2016
23. Li GH, Wang DL, Hu YD, et al: Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. Med Oncol 27:919-925, 2010
24. 3 receptor antagonist. Eur J Cancer Care (Engl) 24:436-443, 2015
25. Molassiotis A, Russell W, Hughes J, et al: The effectiveness of acupressure for the control and management of chemotherapy-related acute and delayed nausea: A randomized controlled trial. J Pain Symptom Manage 47:12-25, 2014
26. Navari RM, Nagy CK, Gray SE: The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655-1663, 2013
27. Navari RM, Nagy CK, Le-Rademacher J, et al: Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting. J Community Support Oncol 14:141-147, 2016
28. Navari RM, Qin R, Ruddy KJ, et al: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134-142, 2016
29. Nishimura J, Satoh T, Fukunaga M, et al: Combination antiemetic therapy with aprepitant/ fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274-1282, 2015
30. Raftopoulos H, Cooper W, O’Boyle E, et al: Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: Results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 23:723-732, 2015
31. Rapoport B, Chua D, Poma A, et al: Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 23:3281-3288, 2015
32. Rapoport B, Schwartzberg L, Chasen M, et al: Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer 57:23-30, 2016
33. Rapoport BL, Chasen MR, Gridelli C, et al: Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: Two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 16:1079-1089, 2015
34. Rithirangsriroj K, Manchana T, Akkayagorn L: Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients. Gynecol Oncol 136:82-86, 2015
35. Roila F, Ruggeri B, Ballatori E, et al: Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: A randomized double-blind study. J Clin Oncol 32: 101-106, 2014
36. Roila F, Ruggeri B, Ballatori E, et al: Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study. Ann Oncol 26:1248-1253, 2015
37. Ruhlmann CH, Christensen TB, Dohn LH, et al: Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): A multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 17:509-518, 2016
38. Ryan JL, Heckler CE, Roscoe JA, et al: Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: A URCC CCOP study of 576 patients. Support Care Cancer 20: 1479-1489, 2012
39. Schmitt T, Goldschmidt H, Neben K, et al: Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: Results of a randomized, placebo-controlled phase III trial. J Clin Oncol 32:3413-3420, 2014
40. Schnadig ID, Agajanian R, Dakhil C, et al: APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol 12: 1469-1481, 2016
41. Schwartzberg LS, Modiano MR, Rapoport BL, et al: Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: A randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16:1071-1078, 2015
42. Stiff PJ, Fox-Geiman MP, Kiley K, et al: Prevention of nausea and vomiting associated with stem cell transplant: Results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19: 49-55.e1, 2013
43. Svanberg A, Birgegård G: Addition of aprepitant (Emend®) to standard antiemetic regimen continued for 7 days after chemotherapy for stem cell transplantation provides significant reduction of vomiting. Oncology 89:31-36, 2015
44. Wang X, Wang L, Wang H, et al: Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys 72:471-473, 2015
45. Weinstein C, Jordan K, Green SA, et al: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: Results of a randomized, double-blind phase III trial. Ann Oncol 27:172-178, 2016
46. Yahata H, Kobayashi H, Sonoda K, et al: Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: A multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491-497, 2016
47. Chiu L, Chow R, Popovic M, et al: Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): A systematic review and meta-analysis. Support Care Cancer 24:2381-2392, 2016
48. Jordan K, Warr DG, Hinke A, et al: Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings-a meta-analysis. Support Care Cancer 24:1941-1954, 2016
49. Lee J, Oh H: Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis. Oncol Nurs Forum 40:163-170, 2013
50. Phillips RS, Friend AJ, Gibson F, et al: Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2: CD007786, 2016
51. Popovic M, Warr DG, Deangelis C, et al: Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): A systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22: 1685-1697, 2014
52. Smith LA, Azariah F, Lavender VT, et al: Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 11:CD009464, 2015
53. Batist G, Gelmon KA, Chi KN, et al: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15:692-700, 2009
54. Cabanillas ME, Schlumberger M, Jarzab B, et al: A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121:2749-2756, 2015
55. Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814-1823, 2015
56. Elisei R, Schlumberger MJ, Müller SP, et al: Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639-3646, 2013
57. Fehrenbacher L, Spira A, Ballinger M, et al: Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837-1846, 2016
58. Finn RS, Crown JP, Lang I, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 16: 25-35, 2015
59. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
60. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
61. Goede V, Fischer K, Busch R, et al: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014
62. Jänne PA, Yang JC, Kim DW, et al: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689-1699, 2015
63. Ko AH, Tempero MA, Shan YS, et al: A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 109:920-925, 2013
64. Kumar SK, LaPlant B, Roy V, et al: Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 5: e338, 2015
65. Larkin J, Ascierto PA, Dréno B, et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876, 2014
66. Lokhorst HM, Plesner T, Laubach JP, et al: Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373:1207-1219, 2015
67. Long GV, Stroyakovskiy D, Gogas H, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444-451, 2015
68. Lonial S, Dimopoulos M, Palumbo A, et al: Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373:621-631, 2015
69. Lonial S, Weiss BM, Usmani SZ, et al: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 387:1551-1560, 2016
70. Mayer RJ, Van Cutsem E, Falcone A, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909-1919, 2015
71. Migden MR, Guminski A, Gutzmer R, et al: Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 16:716-728, 2015
72. Moreau P, Masszi T, Grzasko N, et al: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374:1621-1634, 2016
73. Motzer RJ, Hutson TE, Glen H, et al: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473-1482, 2015
74. Ou SH, Ahn JS, De Petris L, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 34:661-668, 2016
75. Richardson PG, Schlossman RL, Alsina M, et al: PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 122:2331-2337, 2013
76. Rodon J, Tawbi HA, Thomas AL, et al: A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res 20:1900-1909, 2014
77. Rosen LS, LoRusso P, Ma WW, et al: A first-inhuman phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Invest New Drugs 34: 604-613, 2016
78. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016
79. San-Miguel JF, Hungria VT, Yoon SS, et al: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15:1195-1206, 2014
80. Schlumberger M, Tahara M, Wirth LJ, et al: Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621-630, 2015
81. Sehn LH, Chua N, Mayer J, et al: Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): A randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081-1093, 2016
82. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016
83. Stilgenbauer S, Eichhorst B, Schetelig J, et al: Venetoclax in relapsed or refractory chronic lym-phocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. Lancet Oncol 17:768-778, 2016
84. Tabernero J, Yoshino T, Cohn AL, et al: Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16: 499-508, 2015
85. Thatcher N, Hirsch FR, Luft AV, et al: Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763-774, 2015
86. Turner NC, Ro J, André F, et al: Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373:209-219, 2015
87. Wilke H, Muro K, Van Cutsem E, et al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 15:1224-1235, 2014
88. Yoshino T, Mizunuma N, Yamazaki K, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 13:993-1001, 2012
89. Aapro M, Rugo H, Rossi G, et al: A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328-1333, 2014
90. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
91. [Erratum: Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:5851, 2005]
92. Hashimoto H, Yanai T, Nagashima K, et al: A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin. J Clin Oncol 34, 2016 (abstr 10111)
93. Di Renzo N, Montanini A, Mannina D, et al: Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma receiving moderately emetogenic chemotherapy containing steroids: Results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 19:1505-1510, 2011
94. Aapro M, Fabi A, Nolè F, et al: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21:1083-1088, 2010
95. Celio L, Frustaci S, Denaro A, et al: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: A randomized, multicenter, phase III trial. Support Care Cancer 19:1217-1225, 2011
96. Wilkie G, Sakr B, Rizack T: Medical marijuana use in oncology: A review. JAMA Oncol 10.1001/jamaoncol.2016.0155 [epub ahead of print on March 17, 2016]
97. Hamada S, Hinotsu S, Kawai K, et al: Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 22:2161-2166, 2014
98. Olver IN, Grimison P, Chatfield M, et al: Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21:1561-1568, 2013
99. Dennis K, Makhani L, Maranzano E, et al: Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: A systematic review of randomized and non-randomized studies. J Radiat Oncol 2:271-284, 2013
100. Abbott B, Ippoliti C, Bruton J, et al: Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 23:265-269, 1999
101. Gibbs SJ, Cassoni AM: A pilot study to evaluate the cost-effectiveness of ondansetron and granisetron in fractionated total body irradiation. Clin Oncol (R Coll Radiol) 8:182-184, 1996
102. Wong RK, Paul N, Ding K, et al: 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: A placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 24:3458-3464, 2006
103. Kirkbride P, Bezjak A, Pater J, et al: Dexamethasone for the prophylaxis of radiation-induced emesis: A National Cancer Institute of Canada Clinical Trials Group phase III study. J Clin Oncol 18: 1960-1966, 2000
104. Dennis K, Zhang L, Lutz S, et al: International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys 84:e49-e60, 2012
105. Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869, 2010
106. Dupuis LL, Taddio A, Kerr EN, et al: Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy 26: 1221-1231, 2006
107. O’Sullivan C, Dupuis LL, Gibson P, et al: Refinement of the symptom screening in pediatrics tool (SSPedi). Br J Cancer 111:1262-1268, 2014
108. Mead H, Cartwright-Smith L, Jones K, et al. Racial and ethnic disparities in U.S. health care: a chartbook. The Commonwealth Fund, New York. 2008.
109. United States Cancer Statistics Working Group: 1999-2012 incidence and mortality Web-based report. Atlanta, GA, US Department of Health and Human Services, 2015
110. National Cancer Institute: SEER cancer statistics review, 1975-2013. http://seer.cancer.gov/csr/1975_2013/
111. American Cancer Society: Cancer facts and figures for African Americans 2016-2018. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-047403.pdf
112. Check DK, Reeder-Hayes KE, Basch EM, et al: Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Res Treat 156:351-359, 2016
113. Samuel CA, Landrum MB, McNeil BJ, et al: Racial disparities in cancer care in the Veterans Affairs health care system and the role of site of care. Am J Public Health 104:S562-S571, 2014 (suppl 4)
114. Gomez DR, Liao KP, Giordano S, et al: Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer: A population-based study. Cancer 119: 1428-1436, 2013
115. Schnipper LE, Davidson NE, Wollins DS, et al: Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. J Clin Oncol 34: 2925-2934, 2016
116. Schnipper LE, Davidson NE, Wollins DS, et al: American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33: 2563-2577, 2015
117. Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7: 46s-51s, 2011 (suppl 3)
118. Dusetzina SB, Winn AN, Abel GA, et al: Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306-311, 2014
119. Centers for Medicare & Medicaid Services: Medicare Part B drug average sales price: Manufacturer reporting of average sales price (ASP) data. https://www.cms.gov/Medicare/Medicare-Fee-for-ServicePart-B-Drugs/McrPartBDrugAvgSalesPrice/index.html
120. Centers for Medicare & Medicaid Services: Home. https://www.cms.gov/
121. Bach PB: Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med 360:626-633, 2009
122. Memorial Sloan Kettering Cancer Center: Methods for drug price calculations. https://www.mskcc.org/sites/default/files/node/25097/documents/ methods-for-drug-price-calculations-12.9.15.pdf
123. Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27: 3868-3874, 2009